Conflicted Medical Journals and the Failure of Trust

Accountability in Research

Volumn 18, Issue 1, 2011, Pages 45-54

  Jureidini, Jon N ^a   McHenry, Leemon B ^b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

clinical trials; conflict of interest; consumer fraud lawsuits; ghostwriting; GlaxoSmithKline; Journal of the American Academy of Child and Adolescent Psychiatry; medical journals; paroxetine (Paxil, Seroxat); retraction; scientific misconduct; Scientific Therapeutics Information; SmithKline Beecham

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); CONFLICT OF INTEREST; DRUG INDUSTRY; ETHICS; HUMAN; INTERPERSONAL COMMUNICATION; PUBLISHING; SCIENTIFIC MISCONDUCT; TRUST;

CLINICAL TRIALS AS TOPIC; CONFLICT OF INTEREST; DRUG INDUSTRY; HUMANS; JOURNALISM, MEDICAL; PUBLISHING; SCIENTIFIC MISCONDUCT; TRUST; TRUTH DISCLOSURE;

EID: 79955081638     PISSN: 08989621     EISSN: 15455815     Source Type: Journal    
DOI: 10.1080/08989621.2011.542683     Document Type: Article

References (33)

1. M.Angell, 2005. The Truth about the Drug Companies: How They Deceive Us and What to Do about It, New York: Random House.
2. Angell, M. (2009). Drug companies and doctors: A story of corruption. New York Review of Books. http://www.nybooks.com/articles/archives/2009/jan/15/drug-companies-doctorsa-story-of-corruption/ (http://www.nybooks.com/articles/archives/2009/jan/15/drug-companies-doctorsa-story-of-corruption/) (Accessed: October 2010).
3. A.Bass, 2008. Side Effects: A Prosecutor, a Whistleblower and a Bestselling Antidepressant on Trial, Chapel Hill: Algonquin.
4. British Broadcasting Corporation (BBC). (2007). British Broadcasting Company, Panorama: Secrets of the Drug Trials, January, 29, 2007. http://news.bbc.co.uk/1/hi/programmes/panorama/6317137.stm (http://news.bbc.co.uk/1/hi/programmes/panorama/6317137.stm) (Accessed: October 2010).
5. C.D.DeAngelis, 2006. The influence of money on medical science. Journal of the American Medical Association, 296 ( 8): 996 – 998. Epub August 7, 2006
6. Dulcan, M. (2005). E-mail to McHenry, November 10, 2005. http://www.healthyskepticism.org/files/news_int/2010/DulcanMcHenry.pdf (http://www.healthyskepticism.org/files/news_int/2010/DulcanMcHenry.pdf) (Accessed: November 2010).
7. Friedman, R. A. (2008). Review of Bass's Side Effects. New England Journal of Medicine, 358(26):2854. http://www.alison-bass.com/NEJMbookreview.pdf (http://www.alison-bass.com/NEJMbookreview.pdf) (Accessed: October 2010).
8. JAACAP. (2000). Instructions for authors. http://www.healthyskepticism.org/files/news_int/2010/JAACAP_author_instructions_2000.pdf (http://www.healthyskepticism.org/files/news_int/2010/JAACAP_author_instructions_2000.pdf) (Accessed: November 2010).
9. JAACAP. (2010). Scientific misconduct and breach of publication ethics. http://www.jaacap.com/authorinfo (http://www.jaacap.com/authorinfo) (Accessed: October 2010).
10. J.Jureidini, and A.Tonkin, 2003. Paroxetine in major depression. Journal of the American Academy of Child and Adolescent Psychiatry, 42 ( 5): 514
11. J.Jureidini,, L.McHenry, and P.Mansfield, 2008. Clinical trials and drug promotion: selective reporting of study 329. International Journal of Risk and Safety in Medicine, 20 ( 1–2): 73 – 81.
12. J.Jureidini, and L.McHenry, 2009. Key opinion leaders and pediatric antidepressant overprescribing. Psychotherapy and Psychosomatics, 78 ( 4): 197 – 201. Epub April 28, 2009
13. Jureidini, J. and Jureidini, E. (2010). Keller citations update. Analysis of 39 papers/letters available since our 2008 analysis that cite the Keller paper. http://www.healthyskepticism.org/global/news/extra/keller_citations_update (http://www.healthyskepticism.org/global/news/extra/keller_citations_update) (Accessed: November 2010).
14. M.B.Keller,, N.D.Ryan,, M.Strober,, R.G.Klein,, S.P.Kutcher,, B.Birmaher,, O.R.Hagino,, H.Koplewicz,, G.A.Carlson,, G.N.Clarke,, G.J.Emslie,, D.Feinberg,, B.Geller,, V.Kusumaker,, G.Papatheodorou,, W.H.Sack,, M.Sweeny,, K.D.Wagner,, E.B.Weller,, N.C.Winters,, R.Oakes, and J.P.McCafferty,. 2001. Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry, 40 ( 7): 762 – 772.
15. W.Kondro, and B.Sibbald, 2004. Drug company experts advised staff to withhold data about SSRI use in children. Canadian Medical Association Journal, 170 ( 5): 783
16. Leddy, C. (2008). The Unhealthy ties that bind FDA to drug firms. Boston Globe. http://www.boston.com/ae/books/articles/2008/07/05/the_unhealthy_ties_that_bind_fda_to_drug_firms/ (http://www.boston.com/ae/books/articles/2008/07/05/the_unhealthy_ties_that_bind_fda_to_drug_firms/) (Accessed: October 2010).
17. A.Martin,, S.V.Faraone,, S.W.Henderson,, J.J.Hudziak,, E.Leibenluft,, J.Piacentini,, B.Stein,, R.D.Todd, and J.Walkup,. 2008. Conflict of interest. Journal of the American Academy of Child and Adolescent Psychiatry, 47 ( 2): 119 – 120.
18. Martin, A. (2010). Letter to Jureidini, July 2, 2010 http://www.healthyskepticism.org/files/news_int/2010/Rejection%20from%20Martin%20Jul02.pdf (http://www.healthyskepticism.org/files/news_int/2010/Rejection%20from%20Martin%20Jul02.pdf) (Accessed: November 2010).
19. L.McHenry, and J.Jureidini, 2008. Industry-sponsored ghostwriting in clinical trial reporting: A case study. Accountability in Research, 15 ( 3): 152 – 167.
20. L.McHenry, 2010. Of sophists and spin-doctors: industry-sponsored ghostwriting and the crisis of academic medicine. Mens Sana Monographs, 8: 129 – 145.
21. S.E.Nissen, 2010. Setting the RECORD straight. Journal of the American Medical Association, 303 ( 12): 1194 – 1195.
22. M.Parsons, 2002. Paroxetine in adolescent major depression. Journal of the American Academy of Child and Adolescent Psychiatry, 41 ( 4): 364
23. J.S.Ross,, K.P.Hill,, D.S.Egilman, and H.M.Krumholz, 2008. Guest authorship and ghostwriting in publications related to rofecoxib: A case study of industry documents from rofecoxib litigation. Journal of the American Medical Association, 299 ( 15): 1800 – 1812.
24. Scientific Therapeutics Information (STI). (2002). The hidden diagnosis. User's guide and speaker training manual. http://www.healthyskepticism.org/files/docs/gsk/paroxetine/Hidden_Diagnosis.pdf (http://www.healthyskepticism.org/files/docs/gsk/paroxetine/Hidden_Diagnosis.pdf) (Accessed: November 2010).
25. SmithKline Beecham (SKB). (1996). A multi-center, double-blind, placebo controlled study of paroxetine and imipramine in adolescents with unipolar major depression 1993/amended 1996. http://www.healthyskepticism.org/documents/Protocol329.pdf (http://www.healthyskepticism.org/documents/Protocol329.pdf) (Accessed: November 2010).
26. SmithKline Beecham (SKB). (1998a). A multi-center, double-blind, placebo controlled study of paroxetine and imipramine in adolescents with unipolar major depression – acute phase, Final clinical report, SB Document Number: BRL-029060/RSD-100TW9/1/CPMS-329, 24 November, 1998. http://www.gsk.com/media/paroxetine/depression_329_full.pdf (http://www.gsk.com/media/paroxetine/depression_329_full.pdf) (Accessed: November 2010).
27. SmithKline Beecham (SKB). (1998b). Seroxat/Paxil adolescent depression: Position piece on Phase III clinical studies. http://www.healthyskepticism.org/documents/documents/19981014PositionPiece.pdf (http://www.healthyskepticism.org/documents/documents/19981014PositionPiece.pdf) (Accessed: October 2010).
28. SmithKline Beecham (SKB). (2000). JAACAP Reviews. http://www.healthyskepticism.org/files/docs/gsk/paroxetine/study329/JAACAPReviews_000.pdf (http://www.healthyskepticism.org/files/docs/gsk/paroxetine/study329/JAACAPReviews_000.pdf) (Accessed: October 2010).
29. SmithKline Beecham (SKB). (2001). Memo from Z Hawkins to all sales representatives selling paxil. http://www.healthyskepticism.org/files/docs/gsk/paroxetine/study329/20010816Hawkinstoreps.pdf (http://www.healthyskepticism.org/files/docs/gsk/paroxetine/study329/20010816Hawkinstoreps.pdf) (Accessed: November 2010).
30. R.Smith, 2005. Medical journals are an extension of the marketing arm of pharmaceutical companies. PloS Medicine, 2: e138
31. R.Smith, 2006. The trouble with medical journals. Journal of the Royal Society of Medicine, 99 ( 3): 115 – 119.
32. M.A.Steinman,, L.A.Bero,, M.M.Chren, and C.S.Landefeld, 2006. Narrative review: The promotion of gabapentin: An analysis of internal industry documents. Annals of Internal Medicine, 145 ( 4): 284 – 293.
33. A.J.Wakefield,, S.H.Murch,, A.Anthony,, J.Linnell,, D.M.Casson,, M.Malik,, M.Berelowitz,, A.P.Dhillon,, M.A.Thomson,, P.Harvey,, A.Valentine,, S.E.Davies, and J.A.Walker-Smith, 2010. Retraction–Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet, 375 ( 9713): 445